Pfizer Inc said on Wednesday it had started the real-time submission of its application seeking Health Canada’s approval of its oral COVID-19 antiviral drug candidate.
The pill, PF-07321332, is designed to block a key enzyme needed for the coronavirus to multiply.
The move comes after the Canadian government announced on Tuesday that it was in advanced talks with Pfizer and Merck & Co Inc regarding a purchase agreement for their COVID-19 antiviral drugs, as the country attempts to control the spread of the Omicron coronavirus variant.
The country has identified seven people with the new variant as of Nov. 30.
The drugmaker last month submitted its application seeking U.S. authorization of the experimental pill, which was shown to cut the chance of hospitalization or death for adults at risk of severe disease by 89 per cent in a clinical trial.
- Life in the forest: How Stanley Park’s longest resident survived a changing landscape
- ‘Love at first sight’: Snow leopard at Toronto Zoo pregnant for 1st time
- Buzz kill? Gen Z less interested in coffee than older Canadians, survey shows
- Carbon rebate labelling in bank deposits fuelling confusion, minister says
Comments